Literature DB >> 23633088

Investigation of the clinicopathological features of fallopian tube malignancy.

Yoshihito Yokoyama1, Masayuki Futagami, Toshio Fujimoto, Yukihiro Terada, Eriko Takatori, Toru Sugiyama, Takeo Otsuki, Nobuo Yaegashi, Takanobu Kojimahara, Hirohisa Kurachi, Hiroshi Nishiyama, Keiya Fujimori, Toru Tase, Hideki Mizunuma.   

Abstract

The present study investigated the clinico-pathological features of fallopian tube malignancy (FTM) and elucidated the biological behavior of this disorder. Data were compiled concerning FTM from 68 patients from 7 institutes. The patients included 60 cases with fallopian tube carcinoma and 8 cases with fallopian tube carcinosarcoma. The clinical stage was stage III or higher in 72% of the cases. A complete response or partial response was achieved in 56 and 10 of the 68 patients with FTM, respectively, indicating a response rate of 97.1%. The median observation period for FTM was 41 months (3 to 126 months). Three of the 19 patients with stage I/II disease (16%) and 31 of the 49 patients with stage III/IV disease (63%) experienced recurrence, with a median progression-free survival of 17.5 months, and a 3-year overall survival of 77.2%. Regarding the site of recurrence, local intraperitoneal recurrence (26.2%) and solitary recurrences in lymph nodes (19.0%) and in the liver (16.7%) were relatively frequent. Secondary debulking surgery (SDS) was performed in 15 patients (44%) out of the 34 recurrent FTMs. Conversely, recurrence was associated with ascites (carcinomatous peritonitis) in 4 of the 34 recurrent patients, but all 4 patients died. The median survival period after recurrence was 28 months: 7.5 and 30 months with and without ascites, respectively (P<0.001). A univariate analysis showed that prognosis was significantly correlated only with whether SDS could be performed. These results suggest that since FTM frequently results in solitary recurrence, aggressive recurrence treatment including SDS could improve prognosis.

Entities:  

Mesh:

Year:  2013        PMID: 23633088     DOI: 10.3892/or.2013.2439

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  2 in total

1.  Spinal Metastases from a Primary Fallopian Tube Serous Adenocarcinoma: A Case Report.

Authors:  Jonathan P Eskander; Eren O Kuris; Andrew J Younghein; Samuel Landsman; Leonard Japko; Mark S Eskander
Journal:  Global Spine J       Date:  2015-03-12

2.  Examination of the Fractalkine and Fractalkine Receptor Expression in Fallopian Adenocarcinoma Reveals Differences When Compared to Ovarian Carcinoma.

Authors:  Hilal Gurler; Virgilia Macias; Andre A Kajdacsy-Balla; Maria V Barbolina
Journal:  Biomolecules       Date:  2015-12-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.